Policy Activity
New Aimed Alliance Article, Published in Journal of Pharmaceutical Policy and Practice, Calls for Preservation of REMS Program
Aimed Alliances Urges Congress to Keep the Current Risk Evaluation and Mitigation Strategies (REMS) Program Intact Report Highlights Need for Policy…
Aimed Alliance Testifies at FDA Committee Hearing on Novel New Drug
Aimed Alliance’s Director of Medical Affairs, Dr. Shannon Ginnan, testified on an innovative buprenorphine subdermal implant under consideration for approval…
Aimed Alliance Signs on to Coalition for Accessible Treatments Letter
Aimed Alliance has signed on to the Coalition for Accessible Treatments’ letter commenting on the proposed rule, Notice of Benefit…
Aimed Alliance Releases Report on the True Drivers of Health Care Costs in US
Aimed Alliance Report Reveals True Drivers of Health Care Costs in the United States America’s Misplaced Anger at Drug Makers:…
Aimed Alliance Calls Pres. Forum on High Drug Prices Unnecessary
Administration Must Instead Focus on Exploitation and Profiteering by Insurers to Address Rising Health Care Costs November 5, 2015 – Washington,…